Abstract
The objective of the present study was to gather information on the influence of Sodium-Glucose Cotransporter 2 inhibitors (SGLT2i) on the risk of developing urinary tract infection (UTI) in patients with type 2 Diabetes Mellitus (T2DM). This is an Integrative Literature Review (ILR) that collected data from the following databases: Virtual Health Library (VHL) and the National Library of Medicine (PubMed). Inclusion criteria were: articles published between 2020 and 2024, in English, Portuguese, or Spanish, free of charge and available in full text. Exclusion criteria included: articles outside the scope of the topic, duplicates, paid-access publications, and monographs. A total of 73 articles were identified, of which 10 remained after selection and analysis using Zotero software. The included studies indicated an association between SGLT2i use and an increased risk of UTI and urogenital infections, mainly related to dapagliflozin, remogliflozin, and glycosuria. Factors such as higher body mass index and female sex play a more relevant role in UTI predisposition than the isolated use of these drugs. Despite the divergences, the benefits of SGLT2 inhibitors outweigh the potential risks, and their use remains recommended, provided that adequate professional supervision is ensured.